Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 Altman Z-Score is 2,070.80 as of Aug. 03, 2026. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, SL Science Holding ranks worse than 107526.77% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
SL Science Holding has a Altman Z-Score of 2,070.80, indicating it is in Grey Zones. This implies that SL Science Holding is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for SL Science Holding's Altman Z-Score or its related term are showing as below:
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
SL Science Holding Altman Z-Score Related Terms
SL Science Holding Altman Z-Score Historical Data
* Premium members only.
The historical data trend for SL Science Holding's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding Altman Z-Score Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
Altman Z-Score
0.00
0.00
0.00
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Altman Z-Score
0.00
0.00
0.00
0.00
0.00
SLBT vs DMRA, BCAX, TYRA: Altman Z-Score Comparison
For the Biotechnology subindustry, SL Science Holding's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where SL Science Holding's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
SL Science Holding's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.3401
+
1.4
*
-1.9468
+
3.3
*
-1.3561
+
0.6
*
3461.349
+
1.0
*
0.7799
=
2,070.80
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
SL Science Holding (SLBT) has a Altman Z-Score of 2,070.80 as of Aug. 03, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on SL Science Holding and its competitors. According to the industry distribution chart, SL Science Holding ranks #999999 out of 930 companies in the Biotechnology industry.
Is SL Science Holding's Altman Z-Score too high?
SL Science Holding's current Altman Z-Score is 2,070.80. The Biotechnology industry median Altman Z-Score is 2.37. SL Science Holding's value of 2,070.80 is 87275.5% above this industry median. Based on the distribution chart, SL Science Holding ranks #999999 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Altman Z-Score compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #999999 out of 930 companies for Altman Z-Score. This places SL Science Holding in the lower half of its industry. The industry median Altman Z-Score is 2.37. SL Science Holding's value of 2,070.80 is 87275.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.37, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SL Science Holding's current Altman Z-Score of 2,070.80 is 87275.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on SL Science Holding and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SL Science Holding's current Altman Z-Score is 2,070.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Altman Z-Score of 2,070.80. The current Altman Z-Score is 2,070.80 and 87275.5% above the Biotechnology industry median of 2.37. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Altman Z-Score is 2,070.80 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
